Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion: Results of the pan american collaborative retina study group at 24 months

Retina

Volumn 30, Issue 7, 2010, Pages 1002-1011

  Wu, Lihteh ^a   Arevalo, J Fernando ^b   Berrocal, Maria H ^c   Maia, Mauricio ^d   Roca, José A ^e   Morales Cantón, Virgilio ^f   Alezzandrini, Arturo A ^g   Díaz Llopis, Manuel J ^h  

^a Instituto de Cirugia Ocular   (Costa Rica)

^b Clinica Oftalmologica Centro Caracas   (Venezuela)

^c UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^d FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^e CLÍNICA RICARDO PALMA   (Peru)

^f HOSPITAL DR LUIS SÁNCHEZ BULNES   (Mexico)

^g UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^h Instituto Oftalmologico de Valencia   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; STEROID;

ADULT; AGED; ARTICLE; CENTRAL RETINA VEIN OCCLUSION; CEREBROVASCULAR ACCIDENT; CONJUNCTIVAL HEMORRHAGE; DRUG DOSE COMPARISON; FEMALE; HEART INFARCTION; HUMAN; HYPEREMIA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RETINA MACULA EDEMA; RETINA MACULA LUTEA; RETROSPECTIVE STUDY; THICKNESS; UVEITIS; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RETINA; RETINAL VEIN OCCLUSION; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 77954723322     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181cea68d     Document Type: Article

References (55)

1. Iturralde D, Spaide RF, Meyerle CB, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 2006;26:279-284.
2. Campochiaro PA, Hafiz G, Shah SM, et al. Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther 2008;16:791-799.
3. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
4. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005;36: 336-339.
5. Jaissle GB, Ziemssen F, Petermeier K, et al. Bevacizumab for treatment of macular edema secondary to retinal vein occlusion [in German]. Ophthalmologe 2006;103:471-475.
6. Spandau UH, Ihloff AK, Jonas JB. Intravitreal bevacizumab treatment of macular oedema due to central retinal vein occlusion. Acta Ophthalmol Scand 2006;84:555-556.
7. Byeon SH, Kwon YA, Oh HS, et al. Short-term results of intravitreal bevacizumab for macular edema with retinal vein obstruction and diabetic macular edema. J Ocul Pharmacol Ther 2007;23:387-394.
8. Costa RA, Jorge R, Calucci D, et al. Intravitreal bevacizumab (Avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina 2007;27:141-149.
9. Ferrara DC, Koizumi H, Spaide RF. Early bevacizumab treatment of central retinal vein occlusion. Am J Ophthalmol 2007;144:864-871. (Pubitemid 350122344)
10. Hsu J, Kaiser RS, Sivalingam A, et al. Intravitreal bevacizumab (Avastin) in central retinal vein occlusion. Retina 2007;27: 1013-1019.
11. Pai SA, Shetty R, Vijayan PB, et al. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol 2007;143:601-606.
12. Priglinger SG, Wolf AH, Kreutzer TC, et al. Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial. Retina 2007; 27: 1004-1012.
13. Schaal KB, Hoh AE, Scheuerle A, et al. Bevacizumab for the treatment of macular edema secondary to retinal vein occlusion [in German]. Ophthalmologe 2007;104:285-289.
14. Stahl A, Agostini H, Hansen LL, Feltgen N. Bevacizumab inretinal vein occlusion-results of a prospective case series. Graefes Arch Clin Exp Ophthalmol 2007;245:1429-1436.
15. Kriechbaum K, Michels S, Prager F, et al. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol 2008;92:518-522.
16. Moschos MM, Moschos M. Intraocular bevacizumab for macular edema due to CRVO. A multifocal-ERG and OCT study. Doc Ophthalmol 2008;116:147-152.
17. Baseline and early natural history report. The Central Vein Occlusion Study. Arch Ophthalmol 1993;lll:1087-1095.
18. Hayreh SS, Klugman MR, Beri M, et al. Differentiation of ischemic from non-ischemic central retinal vein occlusion during the early acute phase. Graefes Arch Clin Exp Ophthalmol 1990;228:201-217.
19. Mohamed Q, Mclntosh RL, Saw SM, Wong TY. Interventions for central retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2007;l 14:507-519, 524. (Pubitemid 46282974)
20. Shima DT, Adamis AP, Ferrara N, et al. Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Mol Med 1995;1:182-193.
21. Pe'er J, Shweiki D, Itin A, et al. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest 1995;72:638-645.
22. Shima DT, Gougos A, Miller JW, et al. Cloning and mRNA expression of vascular endothelial growth factor in ischemic retinas of Macaca fascicularis. Invest Ophthalmol Vis Sci 1996;37:1334-1340.
23. Pe'er J, Folberg R, Itin A, et al. Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology 1998;105:412-416.
24. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-1487.
25. Noma H, Funatsu H, Mimura T, et al. Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion. Ophthalmology 2009;116:87-93.
26. Boyd SR, Zachary I, Chakravarthy U, et al. Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Arch Ophthalmol 2002;120:1644-1650.
27. Tolentino MJ, Miller JW, Gragoudas ES, et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 1996;103:1820-1828.
28. Hofman P, van Blijswijk BC, Gaillard PJ, et al. Endothelial cell hypertrophy induced by vascular endothelial growth factor in the retina: new insights into the pathogenesis of capillary nonperfusion. Arch Ophthalmol 2001;119:861-866.
29. Adamis AP, Shima DT, Tolentino MJ, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemiaassociated iris neovascularization in a nonhuman primate. Arch Ophthalmol 1996;114:66-71.
30. Rensch F, Jonas JB, Spandau UH. Early intravitreal bevacizumab for non-ischaemic branch retinal vein occlusion. Ophthalmologica 2009;223:124-127.
31. Funk M, Kriechbaum K, Prager F, et al. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest Ophthalmol Vis Sci 2009;50:1025-1032.
32. Spaide RF, Chang LK, Klancnik JM, et al. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol 2009;147:298-306.
33. Pieramici DJ, Rabena M, Castellarin AA, et al. Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions. Ophthalmology 2008;115:e47-e54.
34. Wroblewski JJ, Wells JA III, Adamis AP, et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Arch Ophthalmol 2009;127:374-380.
35. Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group. Arch Ophthalmol 1997;115:486-491.
36. Shetty R, Pai SA, Vincent A, et al. Electrophysiological and structural assessment of the central retina following intra vitreal injection of bevacizumab for treatment of macular edema. Doc Ophthalmol 2008;116:129-135.
37. Prager F, Michels S, Kriechbaum K, et al. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthalmol 2009;93:452-456.
38. Beutel J, Ziemssen F, Luke M, et al. Intravitreal bevacizumab treatment of macular edema in central retinal vein occlusion: one-year results. Int Ophthalmol [E-pub December 20, 2008: DOI 10.1007/sl0792-008-9282-7].
39. Browning DJ, Glassman AR, Aiello LP, et al. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology 2007;114:525-536.
40. Ota M, Tsujikawa A, Kita M, et al. Integrity of foveal photoreceptor layer in central retinal vein occlusion. Retina 2008;28: 1502-1508.
41. Hoeh AE, Ach T, Schaal KB, et al. Long-term follow-up of OCT-guided bevacizumab treatment of macular edema due to retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2009;247:1635-1641.
42. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol 1999;117:1329-1345.
43. Hayreh SS. Prevalent misconceptions about acute retinal vascular occlusive disorders. Prog Retin Eye Res 2005;24:493-519.
44. Christoffersen NL, Larsen M. Pathophysiology and hemodynamics of branch retinal vein occlusion. Ophthalmology 1999; 106:2054-2062.
45. Schultz A, Lavie L, Hochberg I, et al. Interindividual hetero geneity in the hypoxic regulation of VEGF: significance for the development of the coronary artery collateral circulation. Circulation 1999;100:547-552.
46. Lin TH, Yen HW, Voon WC, et al. Vascular endothelial growth factor in coronary sinus: evidence for its association with coronary collaterals. Scand Cardiovasc J 2005;39:353-357.
47. Takahashi K, Muraoka K, Kishi S, Shimizu K. Formation of retinochoroidal collaterals in central retinal vein occlusion. Am J Ophthalmol 1998;126:91-99. (Pubitemid 28341223)
48. Julien S, Heiduschka P, Hofmeister S, Schraermeyer U. Immunohistochemical localisation of intravitreally injected bevacizumab at the posterior pole of the primate eye: implication for the treatment of retinal vein occlusion. Br J Ophthalmol 2008;92:1424-1428.
49. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331-335.
50. Holekamp NM, Bouck N, Volpert O. Pigment epitheliumderived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration. Am J Ophthalmol 2002;134:220-227.
51. Matsumoto Y, Freund KB, Peiretti E, et al. Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease. Retina 2007;27:426-431.
52. Hayreh SS. Retinal vein occlusion. Indian J Ophthalmol 1994; 42:109-132.
53. Arias L, Caminal JM, Casas L, et al. A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Br J Ophthalmol 2008;92:1636-1641.
54. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008;145:239-248.
55. Spaide R. Ranibizumab according to need: a treatment for agerelated macular degeneration. Am J Ophthalmol 2007;143: 679-680.